iwCLL 2019 | The value of MRD assessment in CLL

Arnon Kater

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, explains the value of measurable residual disease (MRD) assessment for chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video